HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia.

Abstract
Although motor impairments in Parkinson's disease (PD) are attributed to nigrostriatal dopaminergic denervation, postural instability and gait difficulty (PIGD) features are less responsive to dopaminergic medications. PIGD features are a risk factor also for the development of dementia in PD (PDD). These observations suggest that nondopaminergic mechanisms may contribute to axial motor impairments. The aim was to perform a correlative PET study to examine the relationship between neocortical β-amyloid deposition ([(11)C]-Pittsburgh Compound B), nigrostriatal dopaminergic denervation ([(11)C]-dihydrotetrabenazine), and PIGD feature severity in PD patients at risk for dementia. This was a cross-sectional study of 44 PD patients (11 female and 33 male; 69.5 ± 6.6 years of age; 7.0 ± 4.8 years motor disease duration; mean H & Y stage: 2.7 ± 0.5) who underwent PET, motor feature severity assessment using the Movement Disorder Society revised UPDRS, and the Dementia Rating Scale (DRS). Linear regression (R(2)(adj) = 0.147; F(4,39) = 2.85; P = 0.036) showed that increased PIGD feature severity was associated with increased neocortical [(11)C]-Pittsburgh Compound B binding (β = 0.346; t(39) = 2.13; P = 0.039) while controlling for striatal [(11)C]-dihydrotetrabenazine binding, age, and DRS total score. Increased neocortical β-amyloid deposition, even at low-range levels, is associated with higher PIGD feature severity in PD patients at risk for dementia. This finding may explain why the PIGD motor phenotype is a risk factor for the development of PDD.
AuthorsMartijn L T M Müller, Kirk A Frey, Myria Petrou, Vikas Kotagal, Robert A Koeppe, Roger L Albin, Nicolaas I Bohnen
JournalMovement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 28 Issue 3 Pg. 296-301 (Mar 2013) ISSN: 1531-8257 [Electronic] United States
PMID23239424 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2012 Movement Disorders Society.
Chemical References
  • 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
  • Amyloid beta-Peptides
  • Aniline Compounds
  • Carbon Isotopes
  • Thiazoles
  • dihydrotetrabenazine
  • Tetrabenazine
Topics
  • Aged
  • Aged, 80 and over
  • Amyloid beta-Peptides (metabolism)
  • Aniline Compounds
  • Carbon Isotopes (pharmacokinetics)
  • Cross-Sectional Studies
  • Dementia (complications)
  • Female
  • Gait Disorders, Neurologic (etiology)
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Parkinson Disease (complications, diagnostic imaging, metabolism)
  • Positron-Emission Tomography
  • Postural Balance (physiology)
  • Psychiatric Status Rating Scales
  • Sensation Disorders (etiology)
  • Severity of Illness Index
  • Tetrabenazine (analogs & derivatives)
  • Thiazoles

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: